Drug
Reteplase clinical trials
Also written CUSA-081.
- studies test it
- 7
- open now
- 1
- in phase 3
- 5
- first study started
- 2003
Keep track of what changes. Save the reteplase studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Development codes
Studies by the year they started
7 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 1
- Phase 3
- 5
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 4
Chiesi Farmaceutici S.p.A. (2) · Angde Biotech Pharmaceutical Co., Ltd. (1) · The University of Texas Health Science Center, Houston (1) · Yongjun Wang (1) · Ge Junbo (1) · Zeenat Qureshi Stroke Institute (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses reteplase is read from its arms, and is right about nine times in ten.
Testing it · 7
- Tenecteplase or Reteplase as Bridging Thrombolysis Before Thrombectomy in Acute Ischemic Cerebrovascular EventsRecruitingPhase 3Yongjun WangNCT07748039Written as Reteplase 10 Units (U) plus a second dose of reteplase 10 U
- Efficacy and Safety of CUSA-081 in the Restoration of Central Venous Access Device (CVAD) FunctionalityTerminatedPhase 3Chiesi Farmaceutici S.p.A.NCT03594175Written as CUSA-081
- Endovascular Stroke Treatment And Reteplase ProtocolWithdrawnPhase 2Zeenat Qureshi Stroke InstituteNCT05900674Written as Reteplase Injection
- A Study of r-PA Treating Patients With Acute Ischemic Stroke（RAISE）CompletedPhase 3Angde Biotech Pharmaceutical Co., Ltd.NCT05295173Written as Injection of recombinant human tissue plasminogen kinase derivatives
- Effect of Low-dose Intracoronary Reteplase on Myocardial Infarct Size During Primary Percutaneous Coronary InterventionTerminatedPhase 3Ge JunboNCT04571580Written as Reteplase Injection 9mg
- Pre-hospital Administration of Thrombolytic Therapy With Urgent Culprit Artery RevascularizationCompletedPhase 4The University of Texas Health Science Center, HoustonNCT00178620Written as Reteplase 10 Units (U) plus a second dose of reteplase 10 U
- Efficacy and Safety of CUSA-081 in the Restoration of Dysfunctional Central Venous Access Device (CVAD) FunctionalityWithdrawnPhase 3Chiesi Farmaceutici S.p.A.NCT03992443Written as CUSA-081
Codes
What other systems call reteplase · ClinicalTrials.gg INT003791
- MeSH (NLM) C087896reteplaseConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) DQA630RIE9RETEPLASEConfirmed FDA, NLM, Wikidata
- RxNorm 76895Confirmed FDA, Wikidata
- Wikidata Q3933703reteplaseConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C90972ReteplaseOne source FDA
- DrugBank DB00015One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C087896 | reteplase | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | DQA630RIE9 | RETEPLASE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 76895 | — | Confirmed FDA, Wikidata |
| Wikidata | Q3933703 | reteplase | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C90972 | Reteplase | One source FDA |
| DrugBank | DB00015 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.